Three Outstanding Growth Companies to Invest in Instantly
Every investor, by nature, is a growth investor, even if their primary focus is income. The stocks that provide a boost to their income also bring joy when their value increases. In this piece, three experts from Our Website have identified some promising growth stocks worth considering for investment right now. These are AstraZeneca (AZN 0.97%), Eli Lilly (LLY 0.06%), and Vertex Pharmaceuticals (VRTX 0.81%).
AstraZeneca: A Hidden Gem with Sky-High Potential
David Jagielski boldly recommends AstraZeneca for being one of the best growth stocks out there, despite its recent six-month drop of more than 11%. With a solid revenue growth of 21% in 2024 and a projected increase in the high single digits for the current year, the stock's impressive future lies in its strategic focus on expanding its oncology, biopharmaceutical, and rare-disease portfolios, fueling a projected sales surge to $80 billion by 2030.
The recent acquisitions from AstraZeneca, such as Amolyt Pharma and Fusion Pharmaceuticals, highlight the company's commitment to innovation and growth. Further, its emphasis on next-gen cancer treatments with radioconjugates underscores its competitive edge in the pharmaceutical market.
Coupled with a P/EG multiple of about 0.9, AstraZeneca's stock offers investor-friendly entry points to capitalize on the company's long-term potential for growth. With a dividend yield of 2%, AstraZeneca's growth potential also comes with some attractive short-term income opportunities.
Eli Lilly: Beyond Weight Loss
Prosper Junior Bakiny sees Eli Lilly as more than just a weight-loss and diabetes company; it's a pharmaceutical leader with a diversified portfolio of blockbuster medications in fields like oncology and immunology. The company's ingenuity and success in the weight-loss market, underpinned by its industry-leading weight loss management drug tirzepatide, have driven impressive revenue and earnings growth.
Eli Lilly will continue to dominate this niche, but its potential goes beyond weight loss. With a robust lineup of potential $1 billion-plus earner drugs—including Alzheimer's disease treatment Kisunla, eczema therapy Ebglyss, and ulcerative colitis drug Omvoh—the company sets itself up for a prosperous future.
Vertex Pharmaceuticals: The Future of Precision Medicine
Keith Speights believes Vertex Pharmaceuticals will deliver tremendous growth in the coming years. With recent FDA approvals for Alyftrek and Journavx, the company is well-equipped to capitalize on emerging opportunities in cystic fibrosis and pain management therapies.
Vertex's new gene-editing therapy Casgevy is already demonstrating promise in the sickle cell disease and transfusion-dependent beta-thalassemia markets. This cutting-edge medical intervention has already been approved in over 50 centers worldwide, and the company anticipates patient growth in the current year.
The company's pipeline is also buzzing with potential. With phase 3 trials for Povetacicept in IgA nephropathy and advancements in zimislecel for severe type 1 diabetes, Vertex is positioned for continued growth and innovation in the pharmaceutical industry.
The Lowdown on Growth Stocks
With AstraZeneca, Eli Lilly, and Vertex Pharmaceuticals at the forefront, there's never been a more exciting time to explore growth stocks within the pharmaceutical sector. Each of these companies is poised for substantial growth in the years to come, thanks to their innovative drug portfolios, robust market positions, and ambitious pipeline initiatives.
- Investors considering growth stocks might want to take a closer look at AstraZeneca, as David Jagielski suggests, due to its potential revenue growth of 21% in 2024 and its focus on expanding its oncology, biopharmaceutical, and rare-disease portfolios.
- In the evaluation of growth stocks, Eli Lilly's diversified portfolio, which includes blockbuster medications in fields like oncology and immunology, should not be overlooked, especially in light of its promising pipeline with potential $1 billion-plus earner drugs.
- AstraZeneca's drop in price over the past six months might mean attractive entry points for investors looking to capitalize on its long-term growth potential, with a solid dividend yield of 2% providing some short-term income opportunities.
- For those interested in investigating growth stocks in the pharmaceutical sector, the projected surge of AstraZeneca's sales to $80 billion by 2030, Eli Lilly's dominance in weight loss and immune disorders, and Vertex Pharmaceuticals' groundbreaking gene-editing therapy in sickle cell disease and beta-thalassemia are all promising indicators of potential returns.
